fbpx Skip to main content

Patients with multiple comorbidities in addition to melanoma may be less likely to receive appropriate treatment than patients without comorbidities. Clinicians and health systems are encouraged to address these inequalities in melanoma treatment.

Disparities in the treatment of patients with melanoma exist in the United States and can have a negative impact on patient outcomes. Curative treatments are available to help improve the prognosis of melanoma in many patients. However, some patients may not be good candidates for curative melanoma treatment, according to an article in Anticancer Research, which could lead to worse disease severity. The objective of the authors was to investigate whether patient demographics have an impact on treatment contraindication in melanoma.

Data was gathered from the National Cancer Database (NCDB) to find patients with melanoma from 2004 to 2015. Researchers used multivariate logistic regression to evaluate independent associations, adjusted for confounders. Patients that did not receive treatment or those with unknown treatment status were excluded.

Out of 499,092 patients, 525 (0.1%) had treatment contraindicated for comorbid conditions (TCBC) and 498,567 (99.9%) of patients received treatment. Patients with government insurance or without insurance were more likely to experience TCBC than patients who had private insurance.

Disparities in demographics and comorbid conditions can have an impact on treatment decisions in patients with melanoma. Comorbidities may affect all levels of melanoma management, including prognosis, treatment, and survival. The extent of TCBC may be more apparent in older patients who may have more comorbidities and decreased immune system function. Clinicians are encouraged to assess the treatment goals of patients who have multiple comorbidities to improve survival or quality of life with melanoma. In addition, healthcare systems are advised to seek ways to address inequalities in melanoma treatment decisions in the United States.

You May Also Like::  Factors Other Than Workplace Tied to COVID-19 Positivity in HCWs

Boczar, D., Bagaria, S. P., Spaulding, A. C., Huayllani, M. T., Avila, F. R., Guliyeva, G., Lu, X., Rinker, B. D., & Forte, A. J. (2021). Treatment Contraindications Based on Comorbidity Status in Patients With Melanoma in the United States. Anticancer Res, 41(4), 2067-2070. https://doi.org/10.21873/anticanres.14976

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More